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Objectives
To assess the cost-effectiveness of screening for open-angle glaucoma (OAG) in the UK; OAG is an important cause of blindness worldwide.
Methods
A Markov Model was developed to estimate lifetime costs and benefits of a cohort of patients facing, alternatively, screening or current opportunistic case finding strategies. Strategies, varying in how screening would be organised, (e.g. invitation for assessment by a glaucoma-trained optometrist (GO) or for simple test assessment by a technician) were developed, and allowed for the progression of OAG and treatment effects. Data inputs were obtained from systematic reviews. Deterministic and probabilistic sensitivity analyses were performed.
Results
Screening was more likely to be cost-effective as prevalence increased, for 40 year olds compared with 60 or 75 year olds, when the re-screening interval was greater (10 years), and for the technician strategy compared with the GO strategy. For each age cohort and at prevalence levels of ≤1%, the likelihood that either screening strategy would be more cost-effective than current practice was small. For those aged 40 'technician screening' compared with current practice has an Incremental Cost Effectiveness Ratio (ICER) that society might be willing to pay when prevalence is 6% to 10% and at over 10% for 60 year olds. In the UK the age specific prevalence of OAG is much lower. Screening by GO, at any age or prevalence level, was not associated with an ICER <£30,000.
Conclusions
Population screening for OAG is unlikely to be cost-effective but could be for specific sub-groups at higher risk.
KEYWORDS
Economic evaluation, Glaucoma, Screening, cost effectiveness analysis, cost utility analysis. Introduction Glaucoma is a progressive optic neuropathy leading to blindness if untreated.
Worldwide, glaucoma is the leading cause of irreversible blindness and openangle glaucoma (OAG) accounts for about 50% of glaucoma blindness (18) . In a developed country setting the majority of OAG cases will remain undiagnosed by current case finding strategies (9) .
Risk factors for developing OAG are raised intraocular pressure (IOP), increasing age, black ethnicity, family history of glaucoma, myopia and diabetes (9) . A key criterion for a screening programme is that early detection leads to a better outcome than late detection. A systematic review (two trials, 500 patients) of treatment effectiveness, demonstrated that treatment reduces the risk of progression in early disease (16) . Population screening for OAG might allow the early treatment and hence reduce the incidence of visual impairment and blindness. However, it is important to know if the screening for OAG is costeffective but existing economic evaluations are insufficient for evidence-based recommendations (13) . The aim of this study was to model the cost-effectiveness of screening for OAG compared with current practice, in the UK, of opportunistic case finding.
Methods
The Model
We developed a Markov Model (MM)( Figure 1 ) (7;20) . Health state definitions (see website, Box 1) were based on the severity of binocular visual field loss, adapted from a scoring system of the integrated visual field, reported by Crabb and colleagues (10 The model allows for a cohort of the population, some with OAG, to pass through different strategies. The model identifies that strategy which leads to the largest proportion of individuals with OAG "crossing the bridge" into treatment ( Figure 1) . A complete version of the model can be obtained from the authors.
Model strategies
We considered three strategies within the model: current practice and two alternative screening strategies. Current UK practice involves the opportunistic identification of cases by community optometrists as part of a routine eye test. 
Glaucoma treatments
Once OAG is diagnosed, we have assumed that treatment would be initiated.
There is a cascade of eye drop treatment options for each disease stage as well as their combination with laser or surgical treatment.
Evidence on their effectiveness suggested that these could be approximated by a single effect size but treatment might vary by OAG severity and progression rate. We assumed initial medical treatment by a beta blocker or prostaglandin analogue, followed by an additional drop of another class of medications if initial treatment was ineffective. For those for whom this fails, argon trabeculoplasty or surgery (trabeculectomy) is the next treatment step. In addition to medications, treatment involves visits to the ophthalmologist every six weeks at the beginning of treatment and a full assessment every six months. After surgery the patient would be seen at an ophthalmology outpatient clinic at one, two, four, eight, 12, and 26 weeks post surgery.
Parameter estimates used in the model
We obtained the model parameter estimates (Table 1 ) from a series of systematic reviews of test accuracy, epidemiology, treatment effectiveness and cost-effectiveness as well as other systematic, focused searches. Detailed description of the parameters estimates can be found in Burr and colleagues (9) . We estimated the treatment costs from a European study including data from 194 patients, containing data for the UK by severity of glaucoma (22) . The likeliest value for the cost of visual impairment was taken to be the mean value of the last two disease stages (22) as these corresponded to the visual impairment category used in this study. We assumed a triangular distribution for probabilistic sensitivity analysis.
Probabilities
We used the NHS fees for optometrists in Scotland for the glaucoma optometrist assessment (2), and costs for the 'technnican screening strategy' from the Scottish Diabetic Retinopathy Screening study (1) , and the screening invitation costs (Table 1 .b) from the same study.
Quality of life and Utilities
We used EQ-5D utility estimates from a recent UK study involving almost 300 participants (8), including a subjective and objective assessment of glaucoma severity. We used the objective scores for each health state for the base case and subjective scores in the sensitivity analysis (Table 1b) . We developed the utility state for visual impairment using weight data for the glaucoma severe state and the relative difference from Gupta and colleagues (12) . We attached Beta distributions to these glaucoma utility weights parameters.(web site Briggs 2006) We assumed that there were no differences in the utility between undiagnosed OAG and treated OAG at each level of severity.
Base case analysis
We ran the base case analysis for cohorts of 40, 60 and 75 year old males, for a range of prevalence values, for a lifetime horizon with screening occurring every three years, and conducted from the UK National Health Service (NHS)
perspective. The cycle length was set at one year and a 3.5% discount rate was used.(web site NICE 2004) The results are presented in incremental costeffectiveness ratios (ICERs). We undertook probabilistic analyses for ranges of OAG prevalence from 0.1% to 10%.
Sensitivity analysis
One way, two-way and multiway sensitivity analyses for the main parameters within the model were conducted, almost all of which were combined with probabilistic sensitivity analysis.
In these analyses we explored the effects of longer screening intervals (e.g. five and ten years) and varying the annual probability of a community optometrist eye test (2%, 13%, 37%) uptake rates using one-way sensitivity analysis. We varied the sensitivity and specificity of the technician test within plausible ranges of 0.5 to 1.0 for sensitivity and 0.8 to 1.0 for specificity.
Additionally, we performed several targeted sensitivity analyses on a 40 year old cohort, at a 5% (except where otherwise stated) OAG prevalence rate and a ten year screening interval (a combination which seemed most likely to be costeffective). As the group of individuals with higher OAG prevalence rate would have a higher chance of visiting the optometrist, we conducted an analysis assuming 1.5 times and twice the probability of having an eye test for current practice strategy. We used alternative triangular probability distributions for progression and incidence using lower and upper base case limits as more likely values. We also explored the impact of using subjective glaucoma severity based health state utilities (8) . We also conducted high and low cost scenario analyses.
Finally, we used one-way sensitivity analysis to identify threshold values for the annual cost of visual impairment to explore the effect of widening the perspective of the analysis. This final analysis was conducted for 1% and 5%
prevalence rate of OAG. Table 2 reports the estimated relative cost-effectiveness by screening strategy at different levels of prevalence of OAG for cohorts aged 40, 60 and 75 years respectively. In each analysis as prevalence increases, costs increase and QALYs fall for all three strategies and all age cohorts. In each analysis at each prevalence level and age group considered, current practice is the least costly but also the least effective of the three strategies. Adopting a 'technician' stategy is more effective but more costly than current practice and screening by a glaucoma optometrist is more effective but more costly than the 'technician' screening strategy.
Results
For each age group considered the ICER from adopting 'technician' screening compared with current practice falls as prevalence increases. Similarly, for each age group considered, the ICER gained from adopting 'glaucoma optometrist' screening compared with 'technician' screening also falls as prevalence increases.
In the base case analysis for a 40 year-olds cohort a 'technician' screening strategy compared with current practice has an ICER that society might be willing to pay when prevalence is approximately 6% to 10% (Table 2) and over 10% for a 60 year-olds. For a 75 year-olds cohort, current practice strategy has an ICER that might be considered worthwhile (Table 2 ) even when prevalence level is 20%
(not shown). Furthermore, for no age cohort and no prevalence level is screening by the glaucoma optometrist instead of screening by the technician associated with an ICER less than £30,000.
Sensitivity analysis performed around the base case
The probabilistic sensitivity analysis (Table 3) indicates for every cohort group and at prevalence levels of 1% or less, the likelihood that any screening strategy would be more cost-effective than current practice is small. At 5% prevalence for the 40 year-olds cohort level there is less than 50% likelihood that 'technician'
screening might be considered cost-effective at a willingness to pay for a QALY of £30,000. Glaucoma optometrist screening is unlikely to be considered costeffective.
Increasing the screening interval reduces the ICER for each age group and each prevalence level, as OAG on average, progresses relatively slowly and QALY reduction is more than compensated for by costs reduction. Varying the annual uptake rates for community optometrist testing led to both cost and QALYs rising as uptake increased. The higher the uptake, the better the current practice strategy performs. The results of the sensitivity analysis on sensitivity and specificity of the test following the measurement of IOP in the 'technician' strategy indicate that the ICER is relatively insensitive to changes in these variables.
Targeted sensitivity analyses
Further sensitivity analysis for a 40 year old cohort, ten year screening interval and a 5% OAG prevalence indicated that screening with the 'technician' strategy might be considered worthwhile (see web site Table 4a ). Probabilistic sensitivity analysis demonstates that the uncertainty around model parameter estimates was important, e.g. even though the ICER for the comparison of the 'technician'
with the current practice strategy is £20,571 there is only 42% likelihood that the cost per QALY would be less than £20,000.
Furthermore, sensitivity analyses on uptake of community optometrist testing demonstrated that the QALY gain for the current practice strategy more than compensates for its' higher cost. The ICER of the 'technician' strategy compared with current practice increased, as did the ICER for the comparison of the 'glaucoma optometrist' strategy compared with the 'technician' strategy.
Changes to the rate of OAG incidence did not greatly alter cost-effectiveness, however, as the rate of progression increased (See web site Table 4 .b 'high') then, the likelihood that either screening strategies could be considered cost-effective increased, as screening is likely to detect more cases and hence delay progression. Using alternative valuations for health utilities, varying the cost of diagnosis by the ophthalmologist, the costs of treatment, inviting people to be screened or their subsequent tests had little effect on cost-effectiveness.
The threshold analysis for the cost of visual impairment and 1% OAG prevalence shows the 'technician' strategy dominates the current practice strategy when the annual cost for visual impairment is around £16,000; moreover, the ICER is less than £30,000 if the cost of visual impairment is greater than £8,800. For the 'glaucoma optometrist' strategy to be considered cost-effective compared with the 'technician' strategy would require the annual cost of visual impairment to be greater than £40,000. (see web site, Figure 2) 
Discussion
We conducted a model based cost-utility analysis of the screening for OAG that all parameter estimates would be useful.
Our study suggests that general population screening is unlikely to be costeffective as the prevalence of OAG in the younger cohorts (estimated 0.9% at aged 50), most likely to enjoy the benefits of screening for longer, is too low.
However, screening might be cost-effective for selected 'at risk' sub-groups.
Targeted screening of 40 to 50 year-olds with a risk factor, (e.g. black ethnicity or those with a family history of glaucoma), is more likely to be cost-effective assuming a prevalence of OAG between 3% to 4% and a screening interval of ten years. These groups account for about 6% of the UK population.
In our model costs increase as prevalence increases because a larger proportion of individuals in the cohort incur the costs of diagnosis and the continuing costs of treating the OAG. The mean cost per person and estimated QALYs are higher for the 40 year-old cohort than the older cohorts because they are less likely to die during the time horizon of the model. Estimated mean QALYs fall as prevalence increases because a greater proportion of the cohort experiences the adverse health effects of OAG.
The model was sensitive to the annual costs for visual impairment (VI). The higher the annual cost of VI the more likely screening to become cost-effective.
The thresholds for this to happen are not dissimilar to the costs estimated by
Meads and Hyde(17) (e.g. annual cost of VI of approximately £7900 for the first year and £7700 for subsequent years).
The more likely people are to have an eye test in the current practice strategy (i.e.
the comparator), the less likely screening is cost-effective. A relative high attendance for eye tests in the current practice setting might explain the somewhat counterintuitive results.
A review of other cost effectiveness evaluations of screening for OAG (13) identified only one previous study that attempted to compare an active screening strategy with current practice (11) . This study also concluded that screening for OAG was not cost-effective. However, a recently published cost-utility analysis of OAG screening in Finland (24) concluded that a screening programme could be cost-effective, especially in older groups where prevalence rates are higher. In contrast to the Finnish analysis our model assumes that no one in the cohorts was receiving treatment prior to screening or opportunistic case detection. The net effect of relaxing this assumption is unclear. Stopping inappropriate glaucoma treatment could make screening more cost-effective. However, care should be taken to consider cost and consequences of those individuals identified as inappropriately treated (e.g. raised IOP but no glaucomatous visual field loss).
Furthermore, if individuals were treated appropriately, there would be no benefit from screening and its cost-effectiveness would be lower. A further factor driving the difference between the conclusions of the Finnish study and our work was the inclusion by the Finnish study of the costs of visual impairment. Our results were also sensitive to the inclusion of these higher costs.
One limitation of our study was that the utility associated with treated and untreated glaucoma was assumed to be the same. This ignores any utility loss associated with adverse effects of treatment. Adverse treatment effects are estimated to reduce quality of life by between 7 and 11% depending upon severity of these effects, as estimated by Burr and colleagues (8) . Future studies should consider using a measure appropriate for use within an economic evaluation in people whose glaucoma has not progressed, both before and after treatment has started.
The systematic review identified insufficient evidence to meaningfully distinguish between the variety of tests that might be used in practice. This led to the simplification of the care pathways where the battery of tests used by a glaucoma optometrist was represented by a single value for sensitivity and specificity of a test. This and other simplifications (such as the small number of stages to represent disease progression) were made following consultation with experts. Further research to develop the model structure and the associated parameter values is required.
Overall, although the evidence on cost-effectiveness should be treated cautiously, the results indicate some patient groups where the organisation of targeted screening, i.e. a surveillance programme, might be given further consideration.
However care pathways would need to be in place for those not eligible for screening. In situations where it might be feasible to organise a service for the target population further primary research on the effectiveness and costeffectiveness of such a programme is required. A randomised controlled trial is the optimal study design but prior to such a study being undertaken further research is needed to develop feasible strategies to identify individuals in 'at risk' groups and the optimal configuration of screening strategies to maximise screening attendance.
Conclusion
General population screening is unlikely to be considered cost effective.
However, screening for OAG is associated with an ICER that society might be willing to pay for particular cohorts of patients, namely, targeted screening for 50
year-olds at high risk (e.g familiy history and/or black ethnicity) may be worthwhile. Results are sensitive to the assumed annual cost of visual impairment.
Further data related to both improving the estimates available for some of the parameters in the model but also from a well designed controlled study comparing viable screening strategies in the cohorts of patients for whom this research has indicated that screening might be potentially cost-effective, are required to confirm the findings.
TABLES WEB SITE Box 1 Definitions of glaucoma health states
No glaucomatous impairment
Under observation as suspect glaucoma but not on medication and no glaucoma visual field defect in either eye
Mild glaucoma
On treatment, no binocular visual field loss, unilateral glaucoma visual field defect present
Moderate glaucoma Up to five missed points (< 10decibels[dB]) in the binocular central 20 degrees of visual field
Severe glaucoma Binocular visual field loss below UK driving standard**
Visual Impairment (includes partial sight and blind)
As per criteria for 'Severe' except binocular visual field loss includes both the upper and lower fields of vision ** 6 or more adjoining missed points (< 10dB), and any additional separate missed point(s) OR a cluster of 4 or more adjoining missed points (<10dB); either of which is either wholly or partly within the central 20 degree superior or inferior hemispheric field. 15.8% GO = 'glaucoma optometrist' strategy; VI = visual impairment * High SA: the likeliest parameter value for the triangular distribution equal to maximum value from base case analysis; maximum value was assumed to be twice the maximum used in the base case (truncated if necessary at 1) and the minimum value was assumed to be equal to the likeliest value from the base case. 
